Toyota is also taking this opportunity to drop the “4X” in the old model’s name. Calling the new car bZ probably won’t shed ...

Click to enlarge Looks great, doesn’t it? These are renders of Perodua’s first EV by Theophilus Chin, based on what we saw (Theo was also there) at the Malaysia Autoshow 2025, which is ongoing at ...

Denmark, oncology-based Pharmacosmos today announced that it has assumed the worldwide rights, excluding select Asia-Pacific ...

The C-HR+ is Toyota’s latest electric SUV to launch in Norway, where nearly all cars sold today are EVs. Toyota calls it “the perfect electric SUV for Norwegian roads,” with a spacious interior and up ...

Perodua is a company that plans everything in detail, and sticks to it. Annual sales records, a vice-like grip of its No.1 ...

Toyota is preparing for its profits to take a big hit this year as Trump’s tariffs take effect. With uncertainty rising in the auto industry, Toyota said it’s “reviewing” its plans to sell 1.5 million ...

Real-world analysis shows BluePrint® identifies chemotherapy-sensitive Basal-type tumors among MammaPrint® High Risk HR+ HER2- breast cancers, supporting more personalized treatment strategies Agendia ...

In general, cancer incidence is projected to rise significantly, with global cases expected to increase by 20% by 2030 and ...

In recent years, the treatment landscape of HR+/HER2−ve breast cancer has completely changed with the introduction of particularly active targeted drugs, from CDK4/6 inhibitors, mTOR inhibitors, and ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Fluence To Contact Him Directly To Discuss Their Options If you ...

HR+/HER2- subtype is the most common. When treated before it has spread, it can have a 100% five-year survival rate. Yet Black women with this diagnosis have worse outcomes than any other ethnic group ...